Aquestive Therapeutics (AQST) announced changes to its leadership team to support the launch of Anaphylm, if approved by the United Stated Food and Drug Administration, FDA, and expansion of its pipeline. Matthew Davis, M.D., RPh will join immediately as Chief Development Officer, CDO; Gary Slatko, M.D., M.B.A, will become interim Chief Medical Officer, CMO; Peter Boyd, M.B.A, has been promoted to Chief People Officer, CPO
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics price target raised to $12 from $9 at Citizens JMP
- Aquestive Therapeutics Secures New Patents for Anaphylm
- Aquestive Therapeutics issued two additional U.S. patents to Anaphylm
- Aquestive Therapeutics Advances Anaphylm Clinical Development
- Aquestive, Veeva, Oklo, BioMarin, TKO: Trending by Analysts